Data Sheet (Cat.No.T211026)

TargetMol

INNO-220

Chemical Properties



CAS No. : 3032576-92-1

Formula: C23H20N4O3

Molecular Weight: 400.43

Storage: Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	INNO-220 is a molecular glue degrader targeting CK1α, exhibiting oral activity and CRBN dependency, capable of inducing cell cycle arrest at G0/G1 phase and apoptosis. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, inhibits the NF-κB signaling pathway, and activates the p53 pathway, making it suitable for lymphoma research.
Targets(IC50)	Apoptosis,Cell Cycle Arrest,Casein Kinase,NF-κB,Molecular Glues,p53
In vitro	INNO-220 (0.0001-10 μM, 72 h) exhibited broad-spectrum antiproliferative activity against wild-type p53 lymphoma cells [1]. INNO-220 (50 nM, 8 h) modulates the p53/NF-κB signaling pathway in OCI-Ly3 and Z-138 cells[1]. INNO-220 (2-1250 nM, 6-24 h) activates p53 by degrading CK1α in OCI-Ly3 cells, Z-138 cells, and OCI-Ly19 cells[1].
In vivo	INNO-220 (3-20 mg/kg, i.g., daily for 43 days) induced tumor regression in DLBCL and MCL xenograft models, inhibited NF-κB activity, and caused no significant changes in mouse body weight [1].

Solubility Information

Solubility	DMSO: 2 mg/mL (4.99 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4973 mL	12.4866 mL	24.9732 mL
5 mM	0.4995 mL	2.4973 mL	4.9946 mL
10 mM	0.2497 mL	1.2487 mL	2.4973 mL
50 mM	0.0499 mL	0.2497 mL	0.4995 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Shi Feng, et al. A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells. Leukemia. 2025 May 27.